Cotellic(R)(cobimetinib); Erivedge(R)(vismodegib); 
Gavreto(R)(pralsetinib); Gazyva(R)/Gazyvaro(R)(obinutuzumab); 
Herceptin(R)(trastuzumab); Kadcyla(R)(trastuzumab emtansine); 
MabThera(R)/Rituxan(R)(rituximab); Perjeta(R)(pertuzumab); 
Polivy(R)(polatuzumab vedotin); Tarceva(R)(erlotinib); 
Rozlytrek(R)(entrectinib); Tecentriq(R)(atezolizumab); 
Venclexta(R)/Venclyxto(R)(venetoclax) in collaboration with AbbVie; 
Xeloda(R)(capecitabine); Zelboraf(R)(vemurafenib). Furthermore, the 
Roche Group has a robust investigational oncology pipeline focusing on 
new therapeutic targets and novel combination strategies. For more 
information on Roche's approach to cancer, visit 
https://www.globenewswire.com/Tracker?data=wYLrMWotXbgyo38hY_qrkj4HHyM_bkeNc08XGZGAY8O8Obt8r9MjxLg2Yy9Sg07-w2aTW__HUnMFOMH20yCXqg== 
www.roche.com. 
 
   About Roche 
 
   Roche is a global pioneer in pharmaceuticals and diagnostics focused on 
advancing science to improve people's lives. The combined strengths of 
pharmaceuticals and diagnostics under one roof have made Roche the 
leader in personalised healthcare -- a strategy that aims to fit the 
right treatment to each patient in the best way possible. 
 
   Roche is the world's largest biotech company, with truly differentiated 
medicines in oncology, immunology, infectious diseases, ophthalmology 
and diseases of the central nervous system. Roche is also the world 
leader in in vitro diagnostics and tissue-based cancer diagnostics, and 
a frontrunner in diabetes management. 
 
   Founded in 1896, Roche continues to search for better ways to prevent, 
diagnose and treat diseases and make a sustainable contribution to 
society. The company also aims to improve patient access to medical 
innovations by working with all relevant stakeholders. More than thirty 
medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2020 employed more than 100,000 people worldwide. 
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 
58.3 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit www.roche.com. 
 
   All trademarks used or mentioned in this release are protected by law. 
 
   Roche Group Media Relations 
 
   Phone: +41 61 688 8888 / e-mail: media.relations@roche.com 
https://www.globenewswire.com/Tracker?data=DbESZDGIxLBapFneCPMCyz6RKa_8ac2Yq94GxXqoJ5bi1dTZHv7twV9PpLmvTEs2PlQysiKM_o9NtGU8z3E0aZq86dhoWByGvJBhKeC1BppwzeCxry9zmYn2hcX4n5l7 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: +41 61 688 31 10     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
Dr. Barbara von Schnurbein 
 Phone: +41 61 687 89 67 
 
 
 
   Attachment 
 
 
   -- 11052021_MR_ASCO 2021 Curtain Raiser 
      https://ml-eu.globenewswire.com/Resource/Download/43804c66-260c-4f72-b10c-3c8849e8b70a

(END) Dow Jones Newswires

May 11, 2021 01:00 ET (05:00 GMT)